The emerging use of aromatase inhibitors for endometriosis treatment

Reproductive Biology and Endocrinology

Review

Warren B Nothnick¹ 

[1] Departments of Obstetrics and Gynecology and Molecular and Integrative Physiology, University of Kansas Medical Center, 3901 Rainbow Boulevard, 66160, Kansas City, KS, USA;

关键词: Endometriosis;    Aromatase Inhibitor;    Letrozole;    Pelvic Pain;    Anastrozole;   

DOI  :  10.1186/1477-7827-9-87

 received in 2010-11-17, accepted in 2011-06-21,  发布年份 2011

来源: Springer

【 摘 要 】

Endometriosis is defined as the growth of endometrial tissue outside of the uterine cavity. The disease occurs primarily in women of reproductive age but recurrent endometriosis is also detected in post-menopausal women. Regardless of age, endometriosis is associated with pain and reduces the quality of life for millions of women world-wide. Conventional therapies focus on reducing systemic levels of estrogen which results in cessation of endometriotic implant growth and pain symptoms associated with the disease. However, these treatments are not effective in all women and are not without side effects. Based upon the discovery that endometriotic tissue over-expresses aromatase, an enzyme critical for estrogen production, emphasis has been placed upon the use of aromatase inhibitors for the treatment of endometriosis and its associated symptoms. This article will review the rationale behind the use of aromatase inhibitors in treating endometriosis and summarize those studies which have evaluated the use of aromatase inhibitors in the treatment of endometriosis and its associated symptoms.

【 授权许可】

CC BY   
© Nothnick; licensee BioMed Central Ltd. 2011